Total Funding
49
Total FundingSeries C raised
Growth Score
pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
75227
Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological.
Stela Gengrinovitch: CO-Founder & Chief Scientist- Ruth Yakar: CEO and Member of the Board of Directors
About the Company
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly
minimizing the systemic toxicity associated with conventional chemotherapy treatments.
